# EDGAR Filing Document

**Accession Number:** 0001567892
**File Stem:** 0001104659-25-091914
**Filing Date:** 2025-9
**Character Count:** 9738
**Document Hash:** 99d2f0a2d8920b8da77f059415b64031
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-091914.hdr.sgml**: 20250922

**ACCESSION NUMBER**: 0001104659-25-091914

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20250922

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250922

**DATE AS OF CHANGE**: 20250922

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Mallinckrodt plc
- **CENTRAL INDEX KEY:** 0001567892
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 981088325
- **STATE OF INCORPORATION:** L2
- **FISCAL YEAR END:** 1226

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35803
- **FILM NUMBER:** 251328551

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** COLLEGE BUSINESS & TECHNOLOGY PARK
- **STREET 2:** CRUISERATH, BLANCHARDSTOWN
- **CITY:** DUBLIN 15
- **PROVINCE COUNTRY:** L2
- **ZIP:** D15
- **BUSINESS PHONE:** 353 1 6960000

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** COLLEGE BUSINESS & TECHNOLOGY PARK
- **STREET 2:** CRUISERATH, BLANCHARDSTOWN
- **CITY:** DUBLIN 15
- **PROVINCE COUNTRY:** L2
- **ZIP:** D15

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d)** 

 **of the Securities Exchange Act of 1934**

 **September 22, 2025**

Date of Report (Date of Earliest Event Reported)

**Mallinckrodt plc**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Ireland** | **001-35803** | **98-1088325** |
| **(State or other jurisdiction<br> of incorporation)** | **(Commission<br> File Number)** | **(IRS Employer <br> Identification No.)** |

---

**College Business & Technology Park, Cruiserath, Blanchardstown, Dublin 15, Ireland**

**(Address of principal executive offices)**

**Registrant's telephone number, including area code: +353 1 696 0000**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

---

| |
|:---|
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

---

Securities registered pursuant to Section 12(b) of the Act: None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

◻ Emerging growth company

◻ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

| | |
|:---|:---|
| **Item 7.01** | **Regulation FD Disclosure.** |

---

On September 22, 2025, Mallinckrodt plc issued a press release announcing the appointment of Dr. Marek Honczarenko as Executive Vice President and Chief Scientific Officer effective September 29, 2025. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference.

The information included in this Item 7.01 and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act") nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

---

| | |
|:---|:---|
| **Item 9.01.** | **Financial Statements and Exhibits.** |

---

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit** | **Description** |
| 99.1 | [Press Release of Mallinckrodt plc dated September 22, 2025.](tm2526613d1_ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **MALLINCKRODT PLC** | **MALLINCKRODT PLC** |
| Date: September 22, 2025 | By: | /s/ Mark Tyndall |
|  | Name: | Mark Tyndall |
|  | Title: | *Executive Vice President, Chief Legal Officer & Corporate Secretary* |

---

## Exhibit 99.1

**Exhibit 99.1**

**Mallinckrodt Names Dr. Marek J. Honczarenko as EVP and Chief Scientific Officer** 

DUBLIN, September 22, 2025 – Mallinckrodt plc today announced the appointment of Dr. Marek J. Honczarenko as Executive Vice President and Chief Scientific Officer, effective September 29, 2025. Dr. Honczarenko, currently the SVP and Head of Development at Sun Pharmaceutical Industries ("Sun Pharma"), will succeed Dr. Peter Richardson, who, as previously announced, has decided to leave the Company to pursue other interests.

At Sun Pharma, Dr. Honczarenko has responsibility for driving strategy and execution of the company's innovative medicines pipeline across all therapeutic areas and regions, including setting the strategic direction for the research and development organization and advancing the company's pipeline of specialty investigational medicines. Dr. Honczarenko's record of success includes delivering approvals for several transformational immunology medicines, including AbbVie's Skyrizi and Rinvoq, GlaxoSmithKline's Benlysta, Nucala, and Jesduvroq, Bristol Myers Squibb's Orencia, and recently Sun Pharma's Leqselvi.

"We are excited to have Marek join Mallinckrodt at a time when we are poised to advance our own pipeline of specialty therapeutics," said Siggi Olafsson, Mallinckrodt's President and Chief Executive Officer. "With the completion in July of our merger with Endo and our plan this year to establish a branded business upon the spin-off of our generics and sterile injectables business, the timing is ideal to welcome someone of Marek's talent, experience, and commitment to building a world-class development team. His background includes successfully launching name-brand products at some of the world's largest and most accomplished pharmaceutical companies. We look forward to the contribution Marek will make to the continued success of Mallinckrodt."

Dr. Honczarenko's background includes a wide range of responsibilities and achievements during his more than 25-year career. Prior to Sun Pharma, he led specialty therapeutic clinical development globally at GlaxoSmithKline; led global immunology development at Abbvie; headed the immunoscience and fibrosis development portfolio at Bristol Myers Squibb; and led the translational immunology organization at Pfizer. Dr. Honczarenko also had leadership roles at MedImmune and Biogen.

He has also served two terms as an Industry Representative for the FDA Arthritis Advisory Committee since October 2019.

"Mallinckrodt is truly dedicated to addressing unmet therapeutic needs for our patients. I am excited to join this exceptional R&D team as we together build an outstanding R&D organization and a new pipeline of therapeutics for the ultimate benefit of the patients we serve," said Dr. Honczarenko.

A medical doctor who has been on faculty at Children's Hospital Boston and Harvard Medical School, Dr. Honczarenko received an MD and PhD *summa cum laude* from Pomeranian Medical University in Poland and completed his post-graduate training at the Department of Pathology and Laboratory Medicine University of Pennsylvania.

**About Mallinckrodt**

Mallinckrodt is dedicated to enhancing lives by providing therapeutics that strive to address unmet patient needs, and is a world-class manufacturer of high-quality generics, sterile injectables, and active pharmaceutical ingredients.

Our company consists of multiple wholly owned subsidiaries that operate in two businesses. Our Brands business is focused on autoimmune and rare diseases in areas including endocrinology, gastroenterology, hepatology, neonatal respiratory critical care, nephrology, neurology, pulmonology, ophthalmology, orthopedics, rheumatology, and urology. Our Par Health business includes generic drugs, sterile injectables, and active pharmaceutical ingredients. To learn more, visit <u>www.MNK-Endo.com</u>.

Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the Company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission ("SEC") disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.

**Contacts**

**Investors**

Juan Avendano

<u>avendano.juan@endo.com</u>

**Media**<br> Linda Huss

<u>Huss.linda@endo.com</u>